Developer docs
API playgroundTry for free, no card

Search company profiles

Andelyn Biosciences

Full company profile

uuid0000ntv

Namestring
Andelyn Biosciences
Legal namestring
Andelyn Biosciences, Inc.
Websiteurl
andelynbio.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Andelyn Biosciences is a privately-held contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with operations centered on viral vector manufacturing in Columbus, Ohio. Originating from gene therapy development and manufacturing operations at Nationwide Children's Hospital, the company operates three specialized facilities totaling more than 225,000 square feet, anchored by the 180,000 sq ft Andelyn Corporate Center (ACC) with 16 modular cGMP manufacturing suites. Its core technology stack consists of the AAV Curator® Platform, which has supported over 100 AAV programs and uses an Optimization-By-Design™ methodology with a clonal HEK293 suspension cell line supporting processes up to 2,000 liters, and the newly launched LVV Curator® Platform extending the same methodology to lentiviral vector manufacturing. Capabilities span plasmid manufacturing, process development, analytical development, quality control, technology transfer, and fill-finish, underpinned by a registered DIGITAL CDMO® digital platform.

The company generates revenue through project-based, multi-year CDMO contracts with biotech, pharmaceutical, academic, government, and nonprofit clients developing therapies primarily for rare and ultra-rare genetic diseases. Service engagements range from early-stage process development and IND-enabling studies through late-stage PPQ manufacturing and BLA-supporting activities, with the company reporting 85+ INDs approved globally and 500+ cGMP clinical batches produced. A secondary revenue stream comes from sublicensing proprietary capsid technologies—including MyoAAV plasmids and Stanton Lab CNS capsids from the Broad Institute, plus AAV-SLB101 from Solid Biosciences—to clients for internal research. Go-to-market is B2B enterprise sales led by a Chief Commercial Officer, supported by ASGCT conference presence, scientific content marketing, and direct business development outreach, with strategic partnerships (e.g., ENCell for US-APAC) extending geographic reach to over 20 countries.

Short descriptiontext

Andelyn Biosciences is a Columbus, Ohio-based cell and gene therapy CDMO providing AAV and lentiviral viral vector manufacturing services from preclinical through commercial stages, serving biotech, pharma, academic, and nonprofit clients developing therapies for rare genetic diseases using its proprietary Curator platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersColumbus, United States
HQ citystring
Columbus
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
viral vector manufacturing, gene therapy CDMO, AAV manufacturing services, lentiviral vector production, cell therapy development
Industry4 codes
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical CDMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Manufacturing Services
TypeProfessional Services
Description

Andelyn Biosciences generates revenue as a CDMO by providing fee-for-service manufacturing of viral vectors (AAV and lentiviral vectors) for cell and gene therapy companies. Services span from plasmid manufacturing through process development, analytical development, cGMP clinical and commercial manufacturing. Revenue is project-based, typically multi-year contracts with milestones.

andelynbio.com
2Platform Licensing
TypeLicensing Royalties
Description

Through licensing agreements, Andelyn sublicenses proprietary capsid technologies (e.g., MyoAAV, Stanton Lab CNS capsids from Broad Institute, AAV-SLB101 from Solid Biosciences) to clients for internal research purposes.

andelynbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Project-based pricing for CDMO services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing varies by project scope, manufacturing requirements, development stage, and regulatory pathway. No public pricing tiers available.

andelynbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1LVV Curator Platform
Description

Standardized lentiviral vector manufacturing platform designed to address the challenge of transitioning cell and gene therapy programs from research-grade processes to GMP production.

contractpharma.com
+2 more records
Core offering1 text field

Andelyn Biosciences is a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that manufactures adeno-associated virus (AAV) and lentiviral viral vectors for biotech and pharmaceutical clients from preclinical through commercial stages. Its proprietary AAV Curator® and LVV Curator® Platforms, supported by integrated plasmid manufacturing, process development, analytical/QC laboratory services, and technology transfer, enable end-to-end contract manufacturing of gene therapies for rare and ultra-rare diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 85+ INDs Approved globally
+4 more records
Product overview1 text field

Andelyn Biosciences is a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) offering a unified platform-plus-services architecture. The core products include the AAV Curator® Platform (supporting over 100 AAV programs) and the LVV Curator® Platform (lentiviral vector manufacturing). These manufacturing platforms are complemented by integrated services including Viral Vector Manufacturing, Plasmid Manufacturing, Process Development, Laboratory Services (Analytical Development and Quality Control), and Technology Transfer. The DIGITAL CDMO® Platform provides digital infrastructure support. The company operates three Columbus, Ohio facilities offering cGMP manufacturing for suspension processes up to 2,000 liters and adherent processes.

Product and service8 records
1AAV Curator® Platform
CategoryGene Therapy Manufacturing Platform
Description

Configurable, data-driven adeno-associated virus (AAV) gene therapy manufacturing platform that has supported over 100 AAV programs using Optimization-By-Design™ methodology. Supports both adherent and suspension processes up to 2,000 liters with a clonal HEK293 suspension cell line and is intended for biotech and pharma clients developing AAV gene therapies.

2LVV Curator® Platform
CategoryCell Therapy Manufacturing Platform
Description

Standardized lentiviral vector (LVV) manufacturing platform built on the Curator® methodology that addresses the transition of cell therapy programs from research-grade processes to GMP manufacturing, using a HEK293 cell line with clinical and regulatory experience. Targeted at cell therapy developers needing GMP-grade LVV for gene modification.

3Viral Vector Manufacturing
CategoryCDMO Manufacturing Services
Description

Full-service cGMP viral vector manufacturing for AAV and lentiviral vectors, including suspension processes up to 2,000 liters and adherent processes, serving biotech and pharma clients from clinical through commercial-scale production.

4Plasmid Manufacturing
CategoryCDMO Manufacturing Services
Description

cGMP plasmid manufacturing services for viral vector production, supporting gene therapy development from preclinical through commercial stages, including FDA Drug Master File support.

5Process Development
CategoryCDMO Development Services
Description

Data-driven, analytical-based process development services that optimize manufacturing workflows for viral vector production, including upstream, downstream, and scale-up activities.

6Laboratory Services
CategoryCDMO Quality and Analytical Services
Description

Comprehensive laboratory services for viral vector programs, encompassing analytical development (safety, purity, potency, yield testing) and quality control release and stability testing, supporting clients through production, purification, release, and stability.

7Technology Transfer
CategoryCDMO Project Services
Description

Technology transfer service for moving established client manufacturing processes into Andelyn's cGMP facilities, enabling continuity of supply across sites and stages.

8DIGITAL CDMO® Platform
CategoryDigital CDMO Platform
Description

Advanced digital model and platform supporting Andelyn's CDMO services, providing data-driven infrastructure for the gene therapy development and manufacturing workflow, including program visibility under the OneTeam™ collaboration model.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership19 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Strategic manufacturing partnership establishing a 'dual hemisphere' workflow between US and Asia-Pacific regions. Combines GMP facilities, technical expertise, and regional networks to reduce regulatory and logistical complexities of international expansion. Enables in-country manufacturing for local clinical trials and patient populations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Clinical manufacturing partnership for AAV gene therapies targeting Limb-Girdle Muscular Dystrophies types 2C and 2D (LGMDR3 and LGMDR5). Andelyn applies its AAV Curator Platform to support IND-enabling studies and GMP manufacturing for Phase I/II clinical trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Partnership to manufacture clinical-grade AAV for gene therapy targeting Nonketotic Hyperglycinemia (NKH), a rare inherited metabolic genetic disorder. Collaboration includes scientists from Dr. Steven Gray's laboratory at UT Southwestern.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

Late-stage PPQ (Process Performance Qualification) manufacturing partnership for JAG201, an investigational gene therapy targeting Phelan-McDermid syndrome (PMS) and SHANK3 haploinsufficiency.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-17
Description

Non-exclusive worldwide licensing agreement for proprietary next-generation capsid AAV-SLB101, which has demonstrated positive safety and efficacy signals in clinical and preclinical studies. Supports development of gene therapies for muscle and cardiac targets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

Partnership for late-stage PPQ manufacturing of AAV gene therapy for CLN2 Batten Disease treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-21
Description

Partnership for scalable manufacturing of clinical-grade AAV material for neuromuscular junction (NMJ) diseases using Andelyn's suspension AAV Curator platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-06
Description

Manufactured viral vector with AAV Curator Platform for Nationwide Children's Hospital's Cellular Therapy and Cancer Immunology Program for Universal-Donor CAR-NK cell therapy clinical trial for AML.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-02-18
Description

Expanded license agreement to include Stanton Lab CNS capsids that increase brain transduction and reduce peripheral organ tropism. Supports gene therapy manufacturing for nervous system disorders with up to 13x more potent neuroretina transduction.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-09
Description

Selected to manufacture clinical-grade AAV for Leber Congenital Amaurosis 16 (LCA16) treatment using suspension AAV Curator Platform. Generating GMP-grade plasmids and vectors.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-08-06
Description

License Agreement for MyoAAV plasmids that produce AAVs 10x more efficient in reaching muscle tissue while de-targeting liver. Includes R&D services, screening, scale-up and preclinical development for IND-enabling studies. Permits sublicensing to clients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-23
Description

Manufacturing partner for CIRM Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC). Manufacturing AAV therapies for rare diseases including Congenital Hereditary Endothelial Dystrophy - Type 1.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-25
Description

Technology transfer and Phase I/II/III manufacturing partnership for GS-100, a suspension process AAV NGLY1 gene therapy for NGLY1 Deficiency treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-15
Description

Partnership for suspension-based AAV gene therapy manufacturing for Charcot-Marie-Tooth Type 1A (CMT1A). Leverages Andelyn's AAV production expertise and proprietary suspension platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-18
Description

Late-stage PPQ manufacturing of UX111 gene therapy for Sanfilippo Syndrome (MPS IIIA). Andelyn successfully manufactured GMP supply for patient dosing and performs PPQ batches necessary for regulatory filings.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-20
Description

NINDS task order team for manufacturing gene therapy for Aspartylglucosaminuria (AGU). Andelyn manufactures plasmids and AAV vector; AmplifyBio performs IND-enabling GLP preclinical studies; Battelle provides assay support.

17The Ohio State University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-09
Description

Collaboration with Ohio State University's Gene Therapy Institute for preclinical and GMP manufacturing of novel gene therapies for neurological disorders including Parkinson's, ALS, and Huntington's disease.

andelynbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-20
Description

Manufacturing partnership for gene therapies targeting chronic kidney diseases. Purespring leverages Andelyn's AAV production experience and suspension platform for preclinical and clinical GMP manufacturing.

19Columbus Innovation District
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Part of the $1.1 billion Columbus Innovation District in Ohio, a collaborative healthcare and life sciences ecosystem including hospital systems, research institutions, and life sciences companies.

associationsnow.com
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Gene therapy CDMO specializing in AAV manufacturing with cGMP production capabilities. Direct competitor serving similar biotech and pharma clients in viral vector manufacturing for gene therapy programs.

TypeBroad incumbent
Description

Global CDMO with substantial cell and gene therapy manufacturing capabilities, including viral vector production through its Paragon and acquired Yposkesi operations. Larger, broader portfolio but directly competes for gene therapy CDMO contracts.

TypeBroad incumbent
Description

One of the largest global CDMOs with established cell and gene therapy services including viral vector and cell therapy manufacturing. Competes for gene therapy CDMO engagements across all stages.

4Yposkesi (Catalent)
TypeDirect peer
Description

Cell and gene therapy CDMO acquired by Catalent, focused on AAV and lentiviral vector manufacturing for rare diseases. Highly comparable service offering and customer base to Andelyn.

TypeDirect peer
Description

Viral vector CDMO specializing in late-stage clinical and commercial manufacturing of oncolytic viruses, gene therapy vectors, and viral vaccines. Direct competitor for viral vector manufacturing services.

TypeDirect peer
Description

European CDMO offering AAV and other viral vector manufacturing for gene therapy clients. Comparable service portfolio targeting similar biotech customer segments.

7Cobra Biologics (Charles River Laboratories)
TypeDirect peer
Description

Viral vector and plasmid DNA CDMO now part of Charles River Laboratories, providing gene therapy and viral vaccine manufacturing services. Direct competitor in viral vector CDMO space.

TypeBroad incumbent
Description

Global CDMO with cell and gene therapy manufacturing capabilities including viral vector production. Broader portfolio but competes directly in gene therapy CDMO engagements.

TypeEmerging player
Description

Clinical-stage biotechnology company developing AAV gene therapies with proprietary NAV technology platform. Notable as both a potential Andelyn client and as a competitor offering licensed capsid technology, similar to Andelyn's Broad Institute licensing model.

TypeEmerging player
Description

Gene therapy developer for Duchenne muscular dystrophy and other neuromuscular diseases with proprietary capsid technology (AAV-SLB101). Andelyn licenses this technology inbound, illustrating the bidirectional client/licensor relationship in gene therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Andelyn Biosciences

Biopharmaceutical CDMO Servicesandelynbio.com

Andelyn Biosciences is a Columbus, Ohio-based cell and gene therapy CDMO providing AAV and lentiviral viral vector manufacturing services from preclinical through commercial stages, serving biotech, pharma, academic, and nonprofit clients developing therapies for rare genetic diseases using its proprietary Curator platforms.

What Andelyn Biosciences does

Andelyn Biosciences is a privately-held contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with operations centered on viral vector manufacturing in Columbus, Ohio. Originating from gene therapy development and manufacturing operations at Nationwide Children's Hospital, the company operates three specialized facilities totaling more than 225,000 square feet, anchored by the 180,000 sq ft Andelyn Corporate Center (ACC) with 16 modular cGMP manufacturing suites. Its core technology stack consists of the AAV Curator® Platform, which has supported over 100 AAV programs and uses an Optimization-By-Design™ methodology with a clonal HEK293 suspension cell line supporting processes up to 2,000 liters, and the newly launched LVV Curator® Platform extending the same methodology to lentiviral vector manufacturing. Capabilities span plasmid manufacturing, process development, analytical development, quality control, technology transfer, and fill-finish, underpinned by a registered DIGITAL CDMO® digital platform.

The company generates revenue through project-based, multi-year CDMO contracts with biotech, pharmaceutical, academic, government, and nonprofit clients developing therapies primarily for rare and ultra-rare genetic diseases. Service engagements range from early-stage process development and IND-enabling studies through late-stage PPQ manufacturing and BLA-supporting activities, with the company reporting 85+ INDs approved globally and 500+ cGMP clinical batches produced. A secondary revenue stream comes from sublicensing proprietary capsid technologies—including MyoAAV plasmids and Stanton Lab CNS capsids from the Broad Institute, plus AAV-SLB101 from Solid Biosciences—to clients for internal research. Go-to-market is B2B enterprise sales led by a Chief Commercial Officer, supported by ASGCT conference presence, scientific content marketing, and direct business development outreach, with strategic partnerships (e.g., ENCell for US-APAC) extending geographic reach to over 20 countries.

Andelyn Biosciences firmographics

Firmographics
Name
Andelyn Biosciences
Legal name
Andelyn Biosciences, Inc.
Website
https://andelynbio.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
251–500 employees
Short description
Andelyn Biosciences is a Columbus, Ohio-based cell and gene therapy CDMO providing AAV and lentiviral viral vector manufacturing services from preclinical through commercial stages, serving biotech, pharma, academic, and nonprofit clients developing therapies for rare genetic diseases using its proprietary Curator platforms.
Ownership category
akta.pro rank

Andelyn Biosciences industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Viral vector manufacturing
  • Gene therapy CDMO
  • AAV manufacturing services
  • Lentiviral vector production
  • Cell therapy development

Where Andelyn Biosciences is headquartered

Location

Headquarters

HQ city
Columbus
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Andelyn Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Manufacturing Services: Andelyn Biosciences generates revenue as a CDMO by providing fee-for-service manufacturing of viral vectors (AAV and lentiviral vectors) for cell and gene therapy companies. Services span from plasmid manufacturing through process development, analytical development, cGMP clinical and commercial manufacturing. Revenue is project-based, typically multi-year contracts with milestones.
  2. Platform Licensing: Through licensing agreements, Andelyn sublicenses proprietary capsid technologies (e.g., MyoAAV, Stanton Lab CNS capsids from Broad Institute, AAV-SLB101 from Solid Biosciences) to clients for internal research purposes.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based pricing for CDMO services

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Andelyn Biosciences product offering

Product offering

Core offering

Andelyn Biosciences is a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that manufactures adeno-associated virus (AAV) and lentiviral viral vectors for biotech and pharmaceutical clients from preclinical through commercial stages. Its proprietary AAV Curator® and LVV Curator® Platforms, supported by integrated plasmid manufacturing, process development, analytical/QC laboratory services, and technology transfer, enable end-to-end contract manufacturing of gene therapies for rare and ultra-rare diseases.

Product overview

Andelyn Biosciences is a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) offering a unified platform-plus-services architecture. The core products include the AAV Curator® Platform (supporting over 100 AAV programs) and the LVV Curator® Platform (lentiviral vector manufacturing). These manufacturing platforms are complemented by integrated services including Viral Vector Manufacturing, Plasmid Manufacturing, Process Development, Laboratory Services (Analytical Development and Quality Control), and Technology Transfer. The DIGITAL CDMO® Platform provides digital infrastructure support. The company operates three Columbus, Ohio facilities offering cGMP manufacturing for suspension processes up to 2,000 liters and adherent processes.

Differentiator

Problem solved

Functional benefit

Brands

  • LVV Curator Platform: Standardized lentiviral vector manufacturing platform designed to address the challenge of transitioning cell and gene therapy programs from research-grade processes to GMP production.
  • AAV Curator Platform
  • DIGITAL CDMO Platform

Products and services

  • AAV Curator® Platform Configurable, data-driven adeno-associated virus (AAV) gene therapy manufacturing platform that has supported over 100 AAV programs using Optimization-By-Design™ methodology. Supports both adherent and suspension processes up to 2,000 liters with a clonal HEK293 suspension cell line and is intended for biotech and pharma clients developing AAV gene therapies.
  • LVV Curator® Platform Standardized lentiviral vector (LVV) manufacturing platform built on the Curator® methodology that addresses the transition of cell therapy programs from research-grade processes to GMP manufacturing, using a HEK293 cell line with clinical and regulatory experience. Targeted at cell therapy developers needing GMP-grade LVV for gene modification.
  • Viral Vector Manufacturing Full-service cGMP viral vector manufacturing for AAV and lentiviral vectors, including suspension processes up to 2,000 liters and adherent processes, serving biotech and pharma clients from clinical through commercial-scale production.
  • Plasmid Manufacturing cGMP plasmid manufacturing services for viral vector production, supporting gene therapy development from preclinical through commercial stages, including FDA Drug Master File support.
  • Process Development Data-driven, analytical-based process development services that optimize manufacturing workflows for viral vector production, including upstream, downstream, and scale-up activities.
  • Laboratory Services Comprehensive laboratory services for viral vector programs, encompassing analytical development (safety, purity, potency, yield testing) and quality control release and stability testing, supporting clients through production, purification, release, and stability.
  • Technology Transfer Technology transfer service for moving established client manufacturing processes into Andelyn's cGMP facilities, enabling continuity of supply across sites and stages.
  • DIGITAL CDMO® Platform Advanced digital model and platform supporting Andelyn's CDMO services, providing data-driven infrastructure for the gene therapy development and manufacturing workflow, including program visibility under the OneTeam™ collaboration model.

Quantifiable outcome

  • 85+ INDs Approved globally
  • +4 more outcomes

Companies that use Andelyn Biosciences

Customer profile

Named customers14 records

Segments3 records

Ideal customer profiles4 records

Andelyn Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Andelyn Biosciences partnerships and signals

Strategic signal

Partnerships

19 partnerships are on record, tiered core and minor.

  • ENCell Co., Ltd.coreStrategic or Co-development Partner · 21 April 2026Strategic manufacturing partnership establishing a 'dual hemisphere' workflow between US and Asia-Pacific regions. Combines GMP facilities, technical expertise, and regional networks to reduce regulatory and logistical complexities of international expansion. Enables in-country manufacturing for local clinical trials and patient populations.
  • Evolyra TherapeuticscoreStrategic or Co-development Partner · 14 April 2026Clinical manufacturing partnership for AAV gene therapies targeting Limb-Girdle Muscular Dystrophies types 2C and 2D (LGMDR3 and LGMDR5). Andelyn applies its AAV Curator Platform to support IND-enabling studies and GMP manufacturing for Phase I/II clinical trials.
  • Drake Rayden FoundationcoreStrategic or Co-development Partner · 17 February 2026Partnership to manufacture clinical-grade AAV for gene therapy targeting Nonketotic Hyperglycinemia (NKH), a rare inherited metabolic genetic disorder. Collaboration includes scientists from Dr. Steven Gray's laboratory at UT Southwestern.
  • Jaguar Gene TherapycoreStrategic or Co-development Partner · 8 December 2025Late-stage PPQ (Process Performance Qualification) manufacturing partnership for JAG201, an investigational gene therapy targeting Phelan-McDermid syndrome (PMS) and SHANK3 haploinsufficiency.
  • Solid BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 17 November 2025Non-exclusive worldwide licensing agreement for proprietary next-generation capsid AAV-SLB101, which has demonstrated positive safety and efficacy signals in clinical and preclinical studies. Supports development of gene therapies for muscle and cardiac targets.
  • Tern TherapeuticscoreStrategic or Co-development Partner · 3 September 2025Partnership for late-stage PPQ manufacturing of AAV gene therapy for CLN2 Batten Disease treatment.
  • Amplo BiotechnologycoreStrategic or Co-development Partner · 21 August 2025Partnership for scalable manufacturing of clinical-grade AAV material for neuromuscular junction (NMJ) diseases using Andelyn's suspension AAV Curator platform.
  • Nationwide Children's HospitalcoreStrategic or Co-development Partner · 6 May 2025Manufactured viral vector with AAV Curator Platform for Nationwide Children's Hospital's Cellular Therapy and Cancer Immunology Program for Universal-Donor CAR-NK cell therapy clinical trial for AML.
  • Broad Institute of MIT and Harvard (Stanton Lab)coreOEM/ Whitelabel/ Licensing Partner · 18 February 2025Expanded license agreement to include Stanton Lab CNS capsids that increase brain transduction and reduce peripheral organ tropism. Supports gene therapy manufacturing for nervous system disorders with up to 13x more potent neuroretina transduction.
  • Hubble TherapeuticscoreStrategic or Co-development Partner · 9 October 2024Selected to manufacture clinical-grade AAV for Leber Congenital Amaurosis 16 (LCA16) treatment using suspension AAV Curator Platform. Generating GMP-grade plasmids and vectors.
  • Broad Institute of MIT and HarvardcoreOEM/ Whitelabel/ Licensing Partner · 6 August 2024License Agreement for MyoAAV plasmids that produce AAVs 10x more efficient in reaching muscle tissue while de-targeting liver. Includes R&D services, screening, scale-up and preclinical development for IND-enabling studies. Permits sublicensing to clients.
  • California Institute for Regenerative Medicine (CIRM)coreStrategic or Co-development Partner · 23 May 2024Manufacturing partner for CIRM Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC). Manufacturing AAV therapies for rare diseases including Congenital Hereditary Endothelial Dystrophy - Type 1.
  • Grace Science, LLCcoreStrategic or Co-development Partner · 25 March 2024Technology transfer and Phase I/II/III manufacturing partnership for GS-100, a suspension process AAV NGLY1 gene therapy for NGLY1 Deficiency treatment.
  • Armatus BiocoreStrategic or Co-development Partner · 15 January 2024Partnership for suspension-based AAV gene therapy manufacturing for Charcot-Marie-Tooth Type 1A (CMT1A). Leverages Andelyn's AAV production expertise and proprietary suspension platform.
  • UltragenyxcoreStrategic or Co-development Partner · 18 December 2023Late-stage PPQ manufacturing of UX111 gene therapy for Sanfilippo Syndrome (MPS IIIA). Andelyn successfully manufactured GMP supply for patient dosing and performs PPQ batches necessary for regulatory filings.
  • Battelle and AmplifyBiocoreStrategic or Co-development Partner · 20 November 2023NINDS task order team for manufacturing gene therapy for Aspartylglucosaminuria (AGU). Andelyn manufactures plasmids and AAV vector; AmplifyBio performs IND-enabling GLP preclinical studies; Battelle provides assay support.
  • The Ohio State UniversitycoreStrategic or Co-development Partner · 9 November 2023Collaboration with Ohio State University's Gene Therapy Institute for preclinical and GMP manufacturing of novel gene therapies for neurological disorders including Parkinson's, ALS, and Huntington's disease.
  • Purespring TherapeuticscoreStrategic or Co-development Partner · 20 October 2023Manufacturing partnership for gene therapies targeting chronic kidney diseases. Purespring leverages Andelyn's AAV production experience and suspension platform for preclinical and clinical GMP manufacturing.
  • Columbus Innovation DistrictminorStrategic or Co-development PartnerPart of the $1.1 billion Columbus Innovation District in Ohio, a collaborative healthcare and life sciences ecosystem including hospital systems, research institutions, and life sciences companies.

Scale indicators10 records

Recent moves2 records

Expansion highlights6 records

Andelyn Biosciences competitors and assessment

Company assessment

Direct peers

  • Forge Biologics: Gene therapy CDMO specializing in AAV manufacturing with cGMP production capabilities. Direct competitor serving similar biotech and pharma clients in viral vector manufacturing for gene therapy programs.
  • Yposkesi (Catalent): Cell and gene therapy CDMO acquired by Catalent, focused on AAV and lentiviral vector manufacturing for rare diseases. Highly comparable service offering and customer base to Andelyn.
  • Vibalogics: Viral vector CDMO specializing in late-stage clinical and commercial manufacturing of oncolytic viruses, gene therapy vectors, and viral vaccines. Direct competitor for viral vector manufacturing services.
  • Biovian: European CDMO offering AAV and other viral vector manufacturing for gene therapy clients. Comparable service portfolio targeting similar biotech customer segments.
  • Cobra Biologics (Charles River Laboratories): Viral vector and plasmid DNA CDMO now part of Charles River Laboratories, providing gene therapy and viral vaccine manufacturing services. Direct competitor in viral vector CDMO space.

Broad incumbents

  • Catalent: Global CDMO with substantial cell and gene therapy manufacturing capabilities, including viral vector production through its Paragon and acquired Yposkesi operations. Larger, broader portfolio but directly competes for gene therapy CDMO contracts.
  • Lonza: One of the largest global CDMOs with established cell and gene therapy services including viral vector and cell therapy manufacturing. Competes for gene therapy CDMO engagements across all stages.
  • AGC Biologics: Global CDMO with cell and gene therapy manufacturing capabilities including viral vector production. Broader portfolio but competes directly in gene therapy CDMO engagements.

Emerging players

  • REGENXBIO: Clinical-stage biotechnology company developing AAV gene therapies with proprietary NAV technology platform. Notable as both a potential Andelyn client and as a competitor offering licensed capsid technology, similar to Andelyn's Broad Institute licensing model.
  • Solid Biosciences: Gene therapy developer for Duchenne muscular dystrophy and other neuromuscular diseases with proprietary capsid technology (AAV-SLB101). Andelyn licenses this technology inbound, illustrating the bidirectional client/licensor relationship in gene therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Andelyn Biosciences social profiles

Digital presence

Andelyn Biosciences compliance and trust

Trust signal

Compliance1 record

Andelyn Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Andelyn Biosciences leadership team

Management profile

Number of profiles

Profiles3 records

Andelyn Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Andelyn Biosciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Andelyn Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Andelyn Biosciences

What does Andelyn Biosciences do?

Andelyn Biosciences is a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that manufactures adeno-associated virus (AAV) and lentiviral viral vectors for biotech and pharmaceutical clients from preclinical through commercial stages. Its proprietary AAV Curator® and LVV Curator® Platforms, supported by integrated plasmid manufacturing, process development, analytical/QC laboratory services, and technology transfer, enable end-to-end contract manufacturing of gene therapies for rare and ultra-rare diseases.

Is Andelyn Biosciences a public or private company?

Andelyn Biosciences is a private company. It is classified as unknown and is currently operating.

When was Andelyn Biosciences founded?

Andelyn Biosciences was founded in 2003. It employs 251 to 500 people.

Where is Andelyn Biosciences based?

Andelyn Biosciences is headquartered in Columbus, United States, in the North America region.

How does Andelyn Biosciences make money?

Two revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are platform Licensing.

Who are Andelyn Biosciences's main competitors?

Direct peers on record are Forge Biologics, Yposkesi (Catalent), Vibalogics, Biovian and Cobra Biologics (Charles River Laboratories). Broad incumbents are Catalent, Lonza and AGC Biologics. Emerging players are REGENXBIO and Solid Biosciences.

Does Andelyn Biosciences have an API?

No public API is recorded for Andelyn Biosciences.

What industry is Andelyn Biosciences in?

Andelyn Biosciences's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalAndelyn partners with Celliaz to advance gene therapy for retinitis pigmentosaAndelyn Biosciences and Celliaz announced a partnership to advance CLZ002, an AAV-based gene therapy for retinitis pigmentosa. Andelyn will provide end-to-end development and manufacturing using its Curator platform. The therapy aims to restore retinal regenerative capacity and is planned for a Phase 1/2 clinical trial.PR NewswireAndelyn Biosciences to Develop and Manufacture AAV Gene Therapy for Celliaz to Treat Retinitis PigmentosaAndelyn Biosciences and Celliaz announced a partnership to develop and manufacture CLZ002, an AAV-based gene therapy for retinitis pigmentosa. Andelyn will use its Curator Suspension Platform for IND-enabling studies and a planned Phase 1/2 trial. The therapy aims to restore retinal regeneration by blocking PROX1 transfer.GenengnewsAndelyn Curator Biomanufacturing Platform Supports Fayuvi Gene Therapy ApprovalAndelyn Biosciences is manufacturing Fayuvi, an FDA-approved gene therapy for Sanfilippo syndrome type A, at its Columbus, OH facility. The therapy, developed by Ultragenyx, is also produced at Ultragenyx's Bedford, MA facility. Fayuvi is the first FDA-approved gene therapy made using Andelyn's AAV Curator Platform.PR NewswireAndelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVITM to Treat Sanfilippo Syndrome Type A (MPS IIAndelyn Biosciences announced it is manufacturing FAYUVI, an FDA-approved gene therapy for Sanfilippo syndrome type A, at its Columbus, Ohio facility. The therapy is the first FDA-approved gene therapy produced using Andelyn's AAV Curator platform. The company expects to support other late-stage clients with its FDA-stamped commercial capabilities.PR NewswireAndelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy ProgramAndelyn Biosciences will support Genprex's diabetes gene therapy program, including scale-up manufacturing and cGMP clinical production. The AAV-based candidate delivers Pdx1 and MafA genes to the pancreas for Type 1 and Type 2 diabetes. Preclinical data in mouse and nonhuman primate models show restored glucose levels and reduced insulin requirements.YahooAndelyn Biosciences to develop GM2 gangliosidosis therapyAndelyn Biosciences has entered a partnership with Queen's University to develop and manufacture AAV9-GM2, a gene therapy targeting GM2 gangliosidoses such as Tay-Sachs and Sandhoff diseases. The collaboration leverages Andelyn's AAV Curator Platform to support the production of the viral vector for upcoming clinical trials.Pharmaceutical TechnologyAndelyn Biosciences to develop GM2 gangliosidosis therapyAndelyn Biosciences has entered a partnership with Queen’s University to develop and manufacture the AAV9-GM2 gene therapy for treating GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases. The collaboration utilizes Andelyn’s AAV Curator Platform to support the progression of this therapy through clinical trials.AijournAndelyn Biosciences to Implement Curator® Platform to Develop and Manufacture Gene Therapy AAV9-GM2 for Queen’s University to Treat GM2 GangliosidosesAndelyn Biosciences has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy candidate for treating GM2 gangliosidoses. Andelyn will utilize its proprietary AAV Curator Platform to execute a multi-phase program aimed at advancing the therapy for clinical dosing.PR NewswireAndelyn Biosciences to Implement Curator® Platform to Develop and Manufacture Gene Therapy AAV9-GM2 for Queen's University to Treat GM2 GangliosidosesAndelyn Biosciences has partnered with Queen's University to develop and manufacture AAV9-GM2, a gene therapy candidate for treating GM2 gangliosidoses such as Tay-Sachs and Sandhoff diseases. The collaboration utilizes Andelyn's AAV Curator® Platform to execute a multi-phase program aimed at advancing the therapy toward patient dosing. This agreement highlights Andelyn's role in providing manufacturing expertise for rare disease treatments.BioPharm InternationalStrategy for Derivation and Optimization of a Clonal HEK293 Suspension Cell Line for High Yield AAV ProductionAndelyn Biosciences scientists derived and characterized a clonal suspension-adapted serum-free (SASF) HEK293 cell line for high-yield recombinant adeno-associated virus (rAAV) production, selecting clone SASF125 as the final candidate for clinical manufacturing. The SASF125 clonal cell line demonstrated superior performance compared to a commercial control cell line, achieving approximately seven-fold increases in rAAV titer for serotypes C and D and outperforming the control in five of six serotypes tested. A GMP Master Cell Bank has been generated, tested, and released for clinical manufacturing of rAAV gene therapy biotherapeutic drugs.